Recent Articles

Retooling NCI MERIT Awards to Support Budding Cancer Researchers

| February 16, 2018 | 0 Comments

Retooling NCI MERIT Awards to Support Budding Cancer Researchers NCI Director Dr. Ned Sharpless discusses how NCI is retooling a grant mechanism, called the MERIT R37 Award, to help early-stage investigators by extending the length of time they can receive funding under their first independent NIH grant.See Original Article

Continue Reading

Abiraterone Approved for Earlier Use in Men with Metastatic Prostate Cancer

| February 15, 2018 | 0 Comments

Abiraterone Approved for Earlier Use in Men with Metastatic Prostate Cancer The Food and Drug Administration (FDA) has expanded the approval of abiraterone (Zytiga®) for men with prostate cancer. The agency approved abiraterone, in combination with the steroid prednisone, for men with metastatic prostate cancer that is responsive to hormone-blocking treatments (also known as castration-sensitive) […]

Continue Reading

For Rare Melanoma, Checkpoint Inhibitors May Hold Substantial Promise

| February 14, 2018 | 0 Comments

For Rare Melanoma, Checkpoint Inhibitors May Hold Substantial Promise A new study suggests that patients with a rare form of melanoma, called desmoplastic melanoma, may be particularly likely to benefit from treatments known as immune checkpoint inhibitors. An NCI-sponsored clinical trial is already testing one such drug in patients with this cancer.See Original Article

Continue Reading

New Cancer Treatment Approach Targets Circadian Clock

| February 13, 2018 | 0 Comments

New Cancer Treatment Approach Targets Circadian Clock Two compounds that target components of the circadian clock killed several types of cancer cells in the lab and slowed the growth of brain tumors in mice without harming healthy cells, a new study showed.See Original Article

Continue Reading

Oncolytic Virus Therapy: Using Tumor-Targeting Viruses to Treat Cancer

| February 9, 2018 | 0 Comments

Oncolytic Virus Therapy: Using Tumor-Targeting Viruses to Treat Cancer A small but growing number of patients with cancer are being treated with oncolytic viruses, which infect and kill tumor cells. But research now suggests that these treatments also work against cancer by spurring an immune response.See Original Article

Continue Reading

FDA Approves New Treatment for Certain Neuroendocrine Tumors

| February 8, 2018 | 0 Comments

FDA Approves New Treatment for Certain Neuroendocrine Tumors People with cancerous neuroendocrine tumors (NETs) that affect the digestive tract now have a new treatment option. On January 29, FDA approved the targeted treatment lutetium Lu 177 dotatate (Lutathera®) for adult patients with advanced NETs that affect the pancreas or gastrointestinal tract.See Original Article

Continue Reading

TARGET Study Finds Major Differences between Childhood and Adult AML

| January 30, 2018 | 0 Comments

TARGET Study Finds Major Differences between Childhood and Adult AML An NCI-funded study has found significant differences in the genetics of acute myeloid leukemia in younger and older patients. The findings could help guide the development of treatments tailored specifically for childhood AML.See Original Article

Continue Reading

Olaparib Approved for Treating Some Breast Cancers with BRCA Gene Mutations

| January 29, 2018 | 0 Comments

Olaparib Approved for Treating Some Breast Cancers with BRCA Gene Mutations The drug olaparib (Lynparza®) is the first treatment approved by the Food and Drug Administration for patients with metastatic breast cancer who have inherited mutations in the BRCA1 or BRCA2 genes.See Original Article

Continue Reading

Study Identifies Potential Cause of Hearing Loss from Cisplatin

| January 26, 2018 | 0 Comments

Study Identifies Potential Cause of Hearing Loss from Cisplatin A new study has found the commonly used chemotherapy drug cisplatin is retained in the inner ear of mice and humans for long periods. The finding may explain why many patients treated with the drug develop hearing loss and could point toward potential ways to prevent […]

Continue Reading

The Challenging Landscape of Cancer and Aging: Charting a Way Forward

| January 24, 2018 | 0 Comments

The Challenging Landscape of Cancer and Aging: Charting a Way Forward NCI Director Dr. Norman Sharpless discusses research on aging and cancer, including understanding the biology of aging and its relationship to cancer, the treatment of older patients, and ensuring older patients participate in cancer clinical trials.See Original Article

Continue Reading